Aug 3, 2026 07:05AM
Aug 3, 2026 07:05AM
Jul 9, 2026 07:35AM
Apr 7, 2026 09:31AM
Apr 7, 2026 08:05AM
Jan 6, 2026 07:26AM
Oct 16, 2025 06:05AM Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
Oct 1, 2025 07:30AM
Sep 17, 2025 07:32AM
Sep 10, 2025 03:07PM
Jul 15, 2025 03:25PM
May 5, 2025 08:00AM
Apr 15, 2025 08:01AM
Apr 10, 2025 08:41AM Biocon Biologics recieves FDA approval for Jobevne
Apr 10, 2025 08:37AM
Mar 7, 2025 08:01AM
Mar 6, 2025 07:00AM
Feb 24, 2025 07:00AM
Dec 2, 2024 07:00AM
Sep 25, 2024 01:05AM
Aug 29, 2024 01:13AM Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
May 21, 2024 08:00AM
Mar 14, 2024 03:29PM
Feb 29, 2024 09:56AM
Jul 3, 2023 12:40PM
Jul 28, 2021 11:29PM
Aug 31, 2020 06:00AM
Jul 21, 2020 02:00AM Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
Jun 11, 2020 06:35PM
Mar 9, 2020 08:05AM
Mar 9, 2020 08:00AM
Dec 2, 2019 07:00AM
Oct 19, 2018 09:31AM
Oct 19, 2018 09:30AM
Sep 21, 2018 09:30AM Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Jun 4, 2018 04:52PM
Jun 1, 2018 05:18PM
Dec 29, 2017 01:30AM
Dec 1, 2017 11:33AM
Dec 1, 2017 11:31AM
Nov 30, 2017 12:55PM
Jul 13, 2017 05:05PM Mylan (MYL) Announces FDA Advisory Committee Unanimously Recommends Approval of Biocon's Proposed Biosimilar Trastuzumab
Jul 13, 2017 05:02PM
Feb 16, 2017 08:13AM
Feb 16, 2017 08:08AM
Jan 11, 2017 08:01AM
Jan 11, 2017 08:00AM
Dec 27, 2016 08:06AM
Dec 27, 2016 08:00AM Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

328,552 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All